Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 304 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: No Investigational Product Clear all
Active, not recruiting Phase 3 Interventional Results available

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pelabresib, Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

NCT07504601
View directory record Official record
Conditions
Healthy Volunteers
Interventions
(2R,6R)-Hydroxynorketamine, Placebo
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and PK Study of OLT1177 Capsules

NCT02134964
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OLT1177 Capsules, Placebo Capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 22, 2026, 12:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 22, 2026, 12:17 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis

NCT03421145
View directory record Official record
Conditions
Plaque
Interventions
3M™ Oral Rinse, Vehicle Control Oral Rinse, PerioShield™ Oral Health Rinse, Water
Device · Other
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 22, 2026, 12:17 PM EDT
Recruiting Phase 4 Interventional

Exparel and Education to Avoid Opioids After Carpal Tunnel Release

NCT03867539
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Differing pain management strategy
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Recruiting Phase 1 Interventional

Mitigating the Pro-inflammatory Phenotype of Obesity

NCT04934228
View directory record Official record
Conditions
Blood Pressure, Diabetes, Obesity, Insulin Resistance, Diuretics Drug Reactions, Sympathetic Nerve Activity
Interventions
Hydrochlorothiazide 12.5Mg Tab, Clonidine Pill, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 22, 2026, 12:17 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Results available

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

NCT00617409
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Paclitaxel, Drug: Ad.p53-DC vaccines, All -trans Retinoic Acid (ATRA)
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

NCT00911170
View directory record Official record
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 2 Interventional

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

NCT04669002
View directory record Official record
Conditions
Ovarian Cancer
Interventions
EP0057, Olaparib tablets
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
11
States / cities
Irvine, California • Lady Lake, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 22, 2026, 12:17 PM EDT
Recruiting No phase listed Observational

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

NCT06636383
View directory record Official record
Conditions
Glycogen Storage Disease Type Ia
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
9
States / cities
Orange, California • Denver, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Not applicable Interventional

Assistive Technology and Reduced Caregiver Burden

NCT05352529
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life, Activities of Daily Living
Interventions
The MapHabit system, Dementia educational videos
Device
Lead sponsor
MapHabit, Inc.
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 22, 2026, 12:17 PM EDT
Recruiting Phase 2Phase 3 Interventional

RAPA-501 Therapy for ALS

NCT04220190
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
RAPA-501 Autologous T stem cells
Biological
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 22, 2026, 12:17 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Immunology of Ebola Vaccine

NCT06100913
View directory record Official record
Conditions
Ebola Virus Disease
Interventions
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Decatur, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Media for Cancer Control (to Prevent Vaping and Smoking Behavior)

NCT04867668
View directory record Official record
Conditions
Tobacco Use
Interventions
Anti-vaping and anti-smoking digital advertising
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 24 Years
Enrollment
2,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 1 Interventional

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

NCT03467789
View directory record Official record
Conditions
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions
Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

NCT04078022
View directory record Official record
Conditions
Shigella
Interventions
SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 22, 2026, 12:17 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers

NCT01199588
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Nexagon® Low Dose, Nexagon® High Dose, Nexagon® Vehicle
Drug
Lead sponsor
OcuNexus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 22, 2026, 12:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

NCT01979887
View directory record Official record
Conditions
Meibomian Glands
Interventions
Meibum Expression
Procedure
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Sep 22, 2026, 12:17 PM EDT